Search Results - "Hlusi, A."

Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation by Stetka, J., Vyhlidalova, P., Lanikova, L., Koralkova, P., Gursky, J., Hlusi, A., Flodr, P., Hubackova, S., Bartek, J., Hodny, Z., Divoky, V.

“…Inflammatory and oncogenic signaling converge in disease evolution of BCR–ABL-negative myeloproliferative neoplasms, clonal hematopoietic stem cell disorders…”
Get full text

Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban by Slavik, L., Jacova, J., Friedecky, D., Ulehlova, J., Tauber, Z., Prochazkova, J., Hlusi, A., Palova, M.

“…The effect of direct oral anticoagulants (DOACs) on laboratory tests dependent on the production of their targets, factor IIa and factor Xa (FXa), is a…”
Get full text

Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single center by Palova, M, Szotkowski, T, Hlusi, A, Indrak, K, Navratilova, J, Divoka, M, Papajik, T

“…Primary myelofibrosis (PMF) is a chronic clonal myeloid disorder. Together with essential thrombocythemia (ET) and polycythemia vera (PV), it belongs to a…”
Get more information

Thrombin Generation Testing in Patients with Myelofibrosis by Palova, M, Slavik, L, Hlusi, A, Szotkowski, T, Ulehlova, J, Divoka, M, Navratilova, J, Papajik, T

“…Primary myelofibrosis (PMF) is a chronic clonal myeloid disorder. Together with essential thrombocythemia (ET) and polycythemia vera (PV), it belongs to a…”
Get more information

Validation of a New Panel of Automated Chemiluminescence Assays for Anticardiolipin Antibodies in the Screening for Antiphospholipid Syndrome by Janek, D, Slavik, L, Ulehlova, J, Krcova, V, Hlusi, A, Prochazkova, J

“…Antibodies anticardiolipin (aCL) and anti-β2-glycoprotein I (aβ2GPI) are two of three laboratory criteria of antiphospholipid syndrome (APS). All of assays of…”
Get more information

C0360: Correlation of Chemiluminescent and Elisa Method for Determination of Anti-Cardiolipin Antibodies by Slavik, L, Prochazkova, J, Janek, D, Ulehlova, J, Wijova, M, Krcova, V, Hlusi, A

Get full text

Detection of clopidogrel resistance using ADP induced aggregometry with specific inhibitor PGE1 by Slavik, L, Ulehlova, J, Krcova, V, Hlusi, A, Indrakova, J, Hutyra, M, Galuszka, J, Indrak, K

“…Antiaggregation therapy is still the most frequently used approach to prevent thrombotic events in cardiovascular diseases. It has a good clinical effect but…”
Get more information

The advantages and limitations of impedance aggregometry in detection of heparin-induced thrombocytopenia by Slavik, L, Svobodova, G, Ulehlova, J, Krcova, V, Hlusi, A, Prochazkova, J, Kaletova, M, Hrckova, Y, Indrak, K

“…Heparin-induced thrombocytopenia (HIT) represents a serious complication of heparin treatment. IgG antibodies binding platelet factor 4 (PF4) and heparin…”
Get more information

Improved pregnancy rate in IVF patients treated with prophylactic low molecular weight heparin (LMWH) by Oborna, I, Brezinova, J, Krcova, V, Fingerova, H, Sobotkova, Z, Hlusi, A, Slavik, L, Ulehlova, J

Get full text

P23 Incidence of thrombophilic markers in women undergoing assisted reproduction (AR) treatment by Oborná, I, Březinová, J, Krčová, V, Fingerová, H, Hluší, A, Slavík, L, Úlehlová, J

Get full text

What is the current treatment of patients with essential thrombocytopenia and other myeloproliferations accompanied with thrombocythemia [correctedand what can be the predictive sign of the risk of thrombosis in such patients--a report from the registry of patients treated by Thromboreductine by Penka, M, Schwarz, J, Pavlík, T, Pytiĺk, R, Doubek, M, Dulícek, P, Kissová, J, Hlusi, A, Schutzová, M, Cerná, O, Brychtová, Y, Szotkowski, T, Volková, Z, Seghetová, J, Vozobulová, V, Hadacová, I, Hochová, I, Voglová, J, Dusek, L

“…The registry of patients treated with Thromboreductine (anagrelid) in the contributing centres in the Czech Republic has been updated with data on the patients…”
Get more information

P080 - Use of abdominal ultrasonography in detection of possible asymptomatic thrombosis in patients with inflammatory bowel disease including evaluation of inherited and acquired prothrombotic factors by Tozzi, I., Procházka, V., Holinka, M., Hluší, A., Zapletalová, J.

Get full text

The occurence of genetic trombophilic markers in patients evaluated for infertility by Filipčíková, R, Březinová, J, Oborná, I, Blažková, Z, Krčová, V, Slavík, L, Ulehlová, J, Hluší, A, Bezdičková, M

“…To assess and compare the frequency of selected gene mutations of thrombophilic markers (FV Leiden, FII prothrombin G20210A and MTHFR C677T) in patients with…”
Get more information

Molecular methods in thrombophilic states diagnostics by Slavík, L, Krcová, V, Hlusí, A, Procházková, J, Ulehlová, J

“…Molecular genetic methods passed into the field of investigation of thrombophilic states in 90th years of last century, along with the first discoveries of…”
Get more information

Essential thrombocythaemia and other myeloproliferative disorders with thrombocythaemia treated with Thromboreductin. A report from the database of register for the 1st quarter of 2010 by Penka, M, Schwarz, J, Ovesná, P, Hlusí, A, Korístek, Z, Doubek, M, Dulícek, P, Pospísilová, D, Kissová, J, Buliková, A, Pavlík, T

“…In the Czech Republic, anagrelid is used according to the recommendations of the Czech Working Group on Myeloproliferative Disorders for treatment…”
Get more information

The results of patients with essentials thrombocythemia and other myeloproliferation-related thrombocythemia--a report of patients treated with Thromboreductin by Penka, M, Schwarz, J, Pavlík, T, Indrák, K, Doubek, M, Dulícek, P, Pospísilová, D, Kissová, J, Jonásová, A, Jelínková, P, Hlusí, A, Schutzová, M, Cerná, O, Brychtová, Y, Nováková, L, Korístek, Z, Segethová, J, Vozobulová, V, Hadacová, I, Hochová, I, Voglová, J, Walterová, L, Bodzásová, C, Dusek, L

“…The registry of patients treated with Thromboreductin (anagrelide) in the Czech Republic contains data concerning patients that have been treated using this…”
Get more information

Essential thrombocytemia and other myeloproliferations with thrombocytemia in the data of the register of patients treated with Thromboreductin till the end of 2006 by Penka, M, Schwarz, J, Pavlík, T, Pytlík, R, Doubek, M, Dulícek, P, Pospísilová, D, Kissová, J, Hlusí, A, Schützová, M, Cerná, O, Brychtová, Y, Szotkowski, T, Volková, Z, Seghetová, J, Vozobulová, V, Hadacová, I, Hochová, I, Voglová, J, Lhotanová, T, Bubeník, B, Zapletal, O, Vránová, M, Micaníková, M, Dusek, L

“…Since 2005, registers of patients treated with Thromboreductin (anagrelid) kept by some centres in the Czech Republic have been supplied with data concerning…”
Get more information

Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR by Penka, M, Doubek, M, Schwarz, J, Pytlík, R, Dulícek, P, Kissová, J, Hlusí, A, Vozobulová, V, Cerná, O, Brychtová, Y, Szotkowski, T, Volková, Z, Seghetová, J, Schutzová, M, Hadacová, I, Hochová, I, Voglová, J, Siroký, O, Belada, D, Lhot'anová, T, Bubeník, B, Vránová, M, Micaníková, M, Dusek, L

“…Anagrelide hydrochloride is an effective drug used in patients with ET and other myeloproliferative disorders with thrombocythemia to selectively decrease the…”
Get more information

Importance of determination of serum beta-2-microglobulin levels in patients with Hodgkin's lymphoma by Raida, L, Papajík, T, Hlusí, A, Faber, E, Urbanová, R, Heczko, M, Jancíková, M, Zapletalová, J, Komenda, S, Indrák, K

“…The authors evaluated retrospectively in a group of 69 adult patients with Hodgkin's lymphoma the relationship between the beta-2-microglobulin serum level,…”
Get more information

Comparison of the effectiveness of idarubicin (Zavedos) and mitoxantrone (Refador) in induction therapy of acute myeloid leukemia in elderly patients (55-75) (a prospective multicenter randomized study conducted 1998-2000 by Indrák, K, Hubácek, J, Mayer, J, Voglová, J, Jarosová, M, Krahulová, M, Malý, J, Faber, E, Penka, M, Kmonícek, M, Jebavý, L, Szotkowski, T, Knotková, R, Hlusí, A, Zapletalová, J

“…The presented study compares the efficacy and the toxicity of idarubicine and mitoxantrone in combination with cytosar (3 + 7) in induction treatment of the…”
Get more information